https://www.live-feeds.com/feed/moderna-shares-double-on-success-of-mrna-cancer-vaccineContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-shares-double-on-success-of-mrna-cancer-vaccinehttps://www.live-feeds.com/feed/moderna-shares-double-on-success-of-mrna-cancer-vaccine#u47090Mon, 24 Aug 2026 02:06:12 +0000Moderna's shares have more than doubled following promising results from its mRNA cancer vaccine, developed in collaboration with Merck, in a late-stage melanoma trial. The vaccine shows potential in preventing skin cancer recurrence. The trial involved over 1,000 patients and demonstrated a significant reduction in cancer recurrence.Why it mattersThe success of Moderna's mRNA cancer vaccine could pave the way for a new wave of cancer treatments. The vaccine uses a personalized neoantigen therapy approach, which involves tailoring the treatment to individual patients. This breakthrou https://www.live-feeds.com/feed/moderna-shares-double-on-success-of-mrna-cancer-vaccinehttps://www.live-feeds.com/feed/moderna-shares-double-on-success-of-mrna-cancer-vaccine#u45943Fri, 21 Aug 2026 19:30:32 +0000Moderna's shares have doubled amid promising results from its mRNA cancer vaccine, developed in collaboration with Merck, in a late-stage melanoma trial. The vaccine shows potential in preventing skin cancer recurrence. Moderna's shares have seen significant fluctuations, rising 8% on Friday.Why it mattersThe success of Moderna's mRNA cancer vaccine marks a significant moment in cancer treatment, offering new hope for patients. The vaccine is a personalized treatment that may help prevent skin cancer from recurring. This development has substantial implications for the future of https://www.live-feeds.com/feed/moderna-shares-double-on-success-of-mrna-cancer-vaccinehttps://www.live-feeds.com/feed/moderna-shares-double-on-success-of-mrna-cancer-vaccine#u45515Thu, 20 Aug 2026 09:27:48 +0000Moderna and Merck's mRNA cancer vaccine showed promise in a late-stage melanoma trial, with Moderna's shares soaring 90%. The vaccine, a collaboration between the two companies, has doubled Moderna's shares. This development could mark a significant moment in cancer treatment.Why it mattersThe mRNA cancer vaccine is a collaboration between Moderna and Merck, two major pharmaceutical companies. The vaccine's success in a late-stage trial could pave the way for a new approach to cancer treatment. Moderna's stock has seen significant gains following the announcement. The